血清心肌肌凝蛋白轻链－I测定在冠心病中的应用

Clinical application of determination of serum cardiac myosin light chain-I in coronary artery disease

急性心肌梗塞（ＡＭＩ）７２例，稳定性心绞痛（ＳＡＰ）１９例和健康人５３例的血清心肌肌凝蛋白轻链－Ｉ（ＣＭＬＣ－Ｉ）测定结果，健康人均在２．１ＯＤＰ／Ｎ以内，按国际公认标准正常值定为＜２．１ＯＤＰ／Ｎ。ＡＭＩ患者的敏感性为９８．６％，特异性为９８．６％，阳性率在发病后４ｈ内达５５．０％，１８天阳性率仍为５４．２％，其阳性出现时间早持续时间长，对诊断ＡＭＩ亦优于ＣＫ－ＭＢ。ＣＭＬＣ－Ｉ的释放持续而稳定，不受心肌灌注血流影响。血清ＣＭＬＣ－Ｉ升高者经物理方法处理后，可分辨出由心肌缺血或心肌坏死所致。

Abstract Determination of serum cardiac myosin light chainI (CMLC-I) was carried out on 72 patients with acute myocardial infarction (AMI), 19 cases of stable angina pectoris (SAP) and 53 healthy persons. International criterion of serum CMLC-I normal value is lower than 2.1 OD P/N. All serum CMLC-I values of the 53 healthy persons were within the limits. Both sensitivity and specificity of CMLC-I in AMI were 98.6%. In serial dertermination of serum CMLC-I in AMI, the positive rate of CMLC-I elevation within 4 hours was obviously higher than that of CK-MB, and this elevation usually lasts for 18 days, which was significantly longer than that of CK-MB.The abnormal values of serum CMLC-I occurred in cases of SAP, while the values returned to within normal limits after physical treatment of the blood samples.